atropine (Rx)

Brand and Other Names:Atreza, Atropine PO, more...SalTropine
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 0.4mg

Sialorrhea, Pylorospasm & Other Spastic Conditions of the Gastrointestinal Tract

0.4 mg PO q4-6hr PRN

Dosage Forms & Strengths

tablet

  • 0.4mg

Sialorrhea, Pylorospasm & Other Spastic Conditions of the Gastrointestinal Tract

3-7 kg: 0.1 mg

8-11 kg: 0.15 mg

11-18 kg: 0.2 mg

18-29 kg: 0.3 mg

≥30 kg: 0.4 mg

Alternate Dosing

  • <5 kg: 0.02 mg/kg/dose initially, then q4-6hr PRN  
  • ≥5 kg: 0.01-0.02 mg/kg PO q4-6hr PRN; not less than 0.1 mg/dose, not to exceed 0.4 mg/dose
Next:

Interactions

Interaction Checker

and atropine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (9)

              • eluxadoline

                atropine, eluxadoline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions. .

              • glucagon

                glucagon increases effects of atropine by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .

              • glucagon intranasal

                glucagon intranasal increases effects of atropine by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .

              • glycopyrronium tosylate topical

                glycopyrronium tosylate topical, atropine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.

              • macimorelin

                atropine, macimorelin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Drugs that may blunt the growth hormone (GH) response to macrimorelin may impact the accuracy of the diagnostic test. Allow sufficient washout time of drugs affecting GH release before administering macimorelin.

              • pramlintide

                pramlintide, atropine. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.

              • revefenacin

                revefenacin and atropine both decrease cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects.

              • secretin

                atropine decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.

              • umeclidinium bromide/vilanterol inhaled

                atropine, umeclidinium bromide/vilanterol inhaled. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Concomitant use with other anticholinergic-containing drugs may lead to additive anticholinergic adverse effects.

              Monitor Closely (100)

              • abobotulinumtoxinA

                abobotulinumtoxinA increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .

              • aclidinium

                atropine and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • amantadine

                atropine, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.

              • amitriptyline

                atropine and amitriptyline both decrease cholinergic effects/transmission. Modify Therapy/Monitor Closely.

              • amoxapine

                atropine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • anticholinergic/sedative combos

                anticholinergic/sedative combos and atropine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • aripiprazole

                atropine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.

                aripiprazole increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • atracurium

                atracurium and atropine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • belladonna alkaloids

                atropine and belladonna alkaloids both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • belladonna and opium

                atropine and belladonna and opium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • benperidol

                atropine decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                benperidol increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • benztropine

                atropine and benztropine both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use.

              • bethanechol

                bethanechol increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • buprenorphine, long-acting injection

                buprenorphine, long-acting injection increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of buprenorphine with anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • carbachol

                carbachol increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • cevimeline

                cevimeline increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • chlorpromazine

                atropine decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.

                chlorpromazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • cisatracurium

                atropine and cisatracurium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • clomipramine

                atropine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • clozapine

                atropine decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.

                clozapine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • cyclizine

                atropine and cyclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • cyclobenzaprine

                atropine and cyclobenzaprine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • darifenacin

                atropine and darifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • dicyclomine

                atropine and dicyclomine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • digoxin

                atropine increases levels of digoxin by unknown mechanism. Use Caution/Monitor.

              • diphenhydramine

                atropine and diphenhydramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • donepezil

                donepezil increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dosulepin

                atropine and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • doxepin

                atropine and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • droperidol

                atropine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                droperidol increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • echothiophate iodide

                echothiophate iodide increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fentanyl

                fentanyl, atropine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl intranasal

                fentanyl intranasal, atropine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl transdermal

                fentanyl transdermal, atropine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl transmucosal

                fentanyl transmucosal, atropine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fesoterodine

                atropine and fesoterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • flavoxate

                atropine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • fluphenazine

                atropine decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.

                fluphenazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • galantamine

                galantamine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • glycopyrrolate

                atropine and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • glycopyrrolate inhaled

                atropine and glycopyrrolate inhaled both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • haloperidol

                atropine decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                haloperidol increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • henbane

                atropine and henbane both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • homatropine

                atropine and homatropine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • huperzine A

                huperzine A increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • hyoscyamine

                atropine and hyoscyamine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • hyoscyamine spray

                atropine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • iloperidone

                atropine decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                iloperidone increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • imipramine

                atropine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • incobotulinumtoxinA

                atropine, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.

              • ipratropium

                atropine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.

              • lofepramine

                atropine and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • loxapine

                atropine decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.

                loxapine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • loxapine inhaled

                loxapine inhaled increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                atropine decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.

              • maprotiline

                atropine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • meclizine

                atropine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • methscopolamine

                atropine and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • metoclopramide intranasal

                atropine will decrease the level or effect of metoclopramide intranasal by Other (see comment). Use Caution/Monitor. Coadministration of metoclopramide intranasal with drugs that impair GI motility may decrease systemic absorption of metoclopramide. Monitor for reduced therapeutic effect.

              • neostigmine

                neostigmine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • nortriptyline

                atropine and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • olanzapine

                atropine decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.

                olanzapine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • oliceridine

                atropine increases toxicity of oliceridine by Other (see comment). Use Caution/Monitor. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.

              • onabotulinumtoxinA

                atropine and onabotulinumtoxinA both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • orphenadrine

                atropine and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • oxybutynin

                atropine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • oxybutynin topical

                atropine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • oxybutynin transdermal

                atropine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • paliperidone

                atropine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                paliperidone increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • pancuronium

                atropine and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • perphenazine

                atropine decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.

                perphenazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • physostigmine

                physostigmine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pilocarpine

                pilocarpine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pimozide

                atropine decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.

                pimozide increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • prabotulinumtoxinA

                atropine, prabotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.

              • pralidoxime

                atropine and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • prochlorperazine

                atropine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

                prochlorperazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • promethazine

                atropine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.

                promethazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • propantheline

                atropine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • protriptyline

                atropine and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • pyridostigmine

                pyridostigmine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • quetiapine

                atropine decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.

                quetiapine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • rapacuronium

                atropine and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • rimabotulinumtoxinB

                atropine, rimabotulinumtoxinB. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Anticholinergics may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.

              • risperidone

                atropine decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                risperidone increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • rocuronium

                atropine and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • scopolamine

                atropine and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • solifenacin

                atropine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • succinylcholine

                succinylcholine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • thioridazine

                atropine decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.

                thioridazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • thiothixene

                atropine decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.

                thiothixene increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • tiotropium

                atropine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • tolterodine

                atropine and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • trifluoperazine

                atropine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.

                trifluoperazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • trihexyphenidyl

                atropine and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.

              • trimipramine

                atropine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • trospium chloride

                atropine and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • umeclidinium bromide

                umeclidinium bromide and atropine both decrease cholinergic effects/transmission. Use Caution/Monitor. If possible, avoid coadministration of additional anticholinergic agents

              • vecuronium

                atropine and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

              • ziprasidone

                atropine decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.

                ziprasidone increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              • zotepine

                atropine decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                atropine decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.

              Minor (25)

              • amitriptyline

                amitriptyline increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              • amoxapine

                amoxapine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              • atenolol

                atropine increases levels of atenolol by unknown mechanism. Minor/Significance Unknown.

              • chlorpromazine

                chlorpromazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.

              • clomipramine

                clomipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              • desipramine

                atropine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.

                desipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              • dimenhydrinate

                dimenhydrinate increases toxicity of atropine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • donepezil

                donepezil decreases effects of atropine by pharmacodynamic antagonism. Minor/Significance Unknown.

              • doxepin

                doxepin increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              • fluphenazine

                fluphenazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.

              • galantamine

                galantamine decreases effects of atropine by pharmacodynamic antagonism. Minor/Significance Unknown.

              • imipramine

                imipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              • levodopa

                atropine, levodopa. Other (see comment). Minor/Significance Unknown. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .

              • lofepramine

                lofepramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              • maprotiline

                maprotiline increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              • nortriptyline

                nortriptyline increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              • perphenazine

                perphenazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.

              • prochlorperazine

                prochlorperazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.

              • promazine

                promazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.

              • promethazine

                promethazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.

              • protriptyline

                protriptyline increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              • thioridazine

                thioridazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.

              • trazodone

                atropine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.

                trazodone increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              • trifluoperazine

                trifluoperazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.

              • trimipramine

                trimipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              Frequency Not Defined

              Ataxia

              Coma

              Confusion

              Delirium

              Dizziness

              Drowsiness

              Hallucinations

              Headache

              Insomnia

              Nervousness

              Arrhythmia

              Flushing

              Hypotension

              Palpitation

              Tachycardia

              Dyspnea

              Laryngospasm

              Pulmonary edema

              Bloating

              Constipation

              Delayed gastric emptying

              Loss of taste

              Nausea

              Paralytic ileus

              Vomiting

              Xerostomia

              Nasal dryness

              Fever

              Anhidrosis

              Urticaria

              Rash

              Scarlantiniform rash

              Urinary hesitancy and retention

              Anaphylaxis

              Angle closure glaucoma

              Blurred vision

              Dry eyes

              Ocular pressure increased

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity to anticholinergic drugs

              Narrow-angle glaucoma, synechia (adhesions) between iris and eye lens, myasthenia gravis, obstructive uropathy, paralytic ileus, severe ulcerative colitis, toxic megacolon, acute hemorrhage with cardiovascular instability, thyrotoxicosis

              Cautions

              Use caution in open-angle glaucoma, hyperthyroidism, BPH, CVD, autonomic neuropathy, HTN, partial obstructive uropathy, toxin-mediated diarrhea, hepatic/renal impairment, tachyarrhythmia, Down syndrome, brain damage in children, salivary secretion disorder, hiatal hernia, reflex esophagitis

              Restrict dose to 2-3 mg (0.03-0.04 mg/kg) in patients with ischemic heart disease, to avoid atropine-induced tachycardia, increased myocardial oxygen demand and potential for worsening cardiac ischemia or increasing infarction size

              Therapy may precipitate acute glaucoma

              Treatment may convert partial organic pyloric stenosis into complete obstruction

              May lead to complete urinary retention in patients with prostatic hypertrophy

              May cause thickening of bronchial secretions and formation of viscid plugs in patients with chronic lung disease

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy

              Drug readily crosses the placental barrier and enters fetal circulation; there are no adequate data on developmental risk associated with use of atropine in pregnant women; adequate animal reproduction studies have not been conducted with atropine

              Lactation

              Drug reported to be excreted in human milk; there are no data on effects of atropine on breastfed infant or effects on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Antimuscarinic; inhibits action of acetylcholine at parasympathetic sites in smooth muscle, CNS, and secretory glands. Increases cardiac output and dries secretions

              Pharmacokinetics

              Metabolism: Liver

              Half-Life: 2.5 hr

              Excretion: Urine

              Absorption: 90%

              Onset: <1 hr

              Duration: 4 hr

              Peak plasma time: 1 hr

              Peak effect: 2 hr

              Previous
              Next:

              Images

              BRAND FORM. UNIT PRICE PILL IMAGE
              atropine injection
              -
              0.4 mg/mL vial
              atropine injection
              -
              0.4 mg/mL vial
              atropine injection
              -
              1 mg/mL vial
              atropine injection
              -
              0.4 mg/mL vial
              atropine injection
              -
              0.4 mg/mL vial
              atropine injection
              -
              0.4 mg/mL vial
              atropine injection
              -
              0.05 mg/mL solution
              atropine injection
              -
              0.1 mg/mL solution
              atropine injection
              -
              0.1 mg/mL solution
              atropine injection
              -
              0.1 mg/mL solution
              atropine injection
              -
              0.4 mg/mL vial
              atropine injection
              -
              0.1 mg/mL solution
              Isopto Atropine ophthalmic (eye)
              -
              1 % drops
              atropine intravenous
              -
              0.4 mg/mL vial
              atropine intravenous
              -
              1 mg/mL vial
              atropine intravenous
              -
              1 mg/mL vial
              atropine ophthalmic (eye)
              -
              1 % drops
              atropine ophthalmic (eye)
              -
              1 % drops
              atropine ophthalmic (eye)
              -
              1 % ointment
              atropine ophthalmic (eye)
              -
              1 % drops

              Copyright © 2010 First DataBank, Inc.

              Previous
              Next:

              Patient Handout

              Select a drug:
              Patient Education
              atropine injection

              NO MONOGRAPH AVAILABLE AT THIS TIME

              USES: Consult your pharmacist.

              HOW TO USE: Consult your pharmacist.

              SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

              PRECAUTIONS: Consult your pharmacist.

              DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

              OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

              NOTES: No monograph available at this time.

              MISSED DOSE: Consult your pharmacist.

              STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

              Information last revised July 2016. Copyright(c) 2021 First Databank, Inc.

              IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.